BioWorld Asia

June 9, 2004

IDM Seeking EUR92 Million In IPO To Fund Programs In Cancer

PARIS - Immuno-Designed Molecules SA proposed an IPO on the Nouveau Marche of the Euronext stock exchange in Paris last week, offering 8.1 million shares at €10.50 to €12.20 per share. (BioWorld International) Read More

UK Researchers Discover Mutant Gene's Role In Type II Diabetes

Countries Throughout The World Promoting Biotech Development

UK Officials Continue Campaign To Improve Biotech Environment

Serono Abandons Emfilermiun, Setting Back Amrad Program

Private Australian Companies Cerylid, Kinacia Merge Efforts

IQ Corp., U.S. Navy Enter Deal To Develop Biodefense Agents

Shareholders Accept Deal To Close Shop At PPL Therapeutics

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan. 13, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for January 13, 2025

Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal

BioWorld

The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...

Proteomics study explores how protein changes influence disease

BioWorld Science

Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...

Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance

BioWorld

Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...